Barclays analyst Luke Sergott maintained a Buy rating on Twist Bioscience (TWST – Research Report) today and set a price target of $52.00. The company’s shares closed last Friday at $52.37.

Scotiabank raised the firm’s price target on Twist Bioscience (TWST) to $62 from $54 and keeps an Outperform rating on the shares. The company’s Q1 results beat consensus and guidance ...

In this article, we are going to take a look at where Twist Bioscience Corporation (NASDAQ:TWST) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall Street’s ...

In this article, we are going to take a look at where Twist Bioscience Corporation (NASDAQ:TWST) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall Street’s ...

Roche Holding AG Akt-0.45% CHF234.65B ...

Twist Bioscience Corporation (NASDAQ:TWST), a synthetic DNA specialist with a market capitalization of $2.8 billion, recently held its Annual Meeting of Stockholders, resulting in significant ...

Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago. These figures ...

TWIST BIOSCIENCE ($TWST) is expected to release its quarterly earnings data on Monday, February 3rd before market open. Analysts are expecting revenue of $88,712,460 ...